Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel/cisplatin to standard radiotherapy with…

By R. Fietkau, M. Hecht, B. Hofner, D. Lubgan, H. Iro, O. Gefeller, C. Rödel, M. Hautmann, O. Kölbl, A. Salay and 11 more. 2020

Subfields: Oncology, Otorhinolaryngology

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Knebel
2. Maximilian Linxweiler
3. S. Körner
4. L. Brust
5. Matthias Schneider
6. F. Braun
7. S. Wemmert
8. J. Kühn

Citations in the corpus

• Expression of 3q Oncogene SEC62 Predicts Survival in Head and Neck Squamous Cell Carcinoma Patients Treated with Primary Chemoradiation (2023, background): “Here, intensity-modulated radiation therapy (IMRT) is combined with cisplatin, which has been shown to achieve three-year locoregional control rates of 55–80% in large-scale, prospective clinical trials [8–12].”